BRPI0413426A - antagonistas de receptor novo - Google Patents
antagonistas de receptor novoInfo
- Publication number
- BRPI0413426A BRPI0413426A BRPI0413426-5A BRPI0413426A BRPI0413426A BR PI0413426 A BRPI0413426 A BR PI0413426A BR PI0413426 A BRPI0413426 A BR PI0413426A BR PI0413426 A BRPI0413426 A BR PI0413426A
- Authority
- BR
- Brazil
- Prior art keywords
- receptor antagonists
- nogo
- new receptor
- nucleic acids
- antigen binding
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 102000005781 Nogo Receptor Human genes 0.000 abstract 3
- 108020003872 Nogo receptor Proteins 0.000 abstract 3
- 102000000343 Nogo Receptor 1 Human genes 0.000 abstract 2
- 108010041199 Nogo Receptor 1 Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2003/025004 WO2004014311A2 (en) | 2002-08-10 | 2003-08-07 | Nogo receptor antagonists |
| PCT/US2004/002702 WO2005016955A2 (en) | 2003-08-07 | 2004-01-30 | Nogo receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0413426A true BRPI0413426A (pt) | 2006-10-17 |
Family
ID=34192565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413426-5A BRPI0413426A (pt) | 2003-08-07 | 2004-01-30 | antagonistas de receptor novo |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1660517A4 (enExample) |
| JP (1) | JP2007501612A (enExample) |
| CN (1) | CN1926147A (enExample) |
| AU (1) | AU2004264405A1 (enExample) |
| BR (1) | BRPI0413426A (enExample) |
| CA (1) | CA2535007A1 (enExample) |
| IS (1) | IS8339A (enExample) |
| MX (1) | MXPA06001444A (enExample) |
| NO (1) | NO20061081L (enExample) |
| PL (1) | PL380274A1 (enExample) |
| WO (1) | WO2005016955A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| CN1681838A (zh) | 2002-08-10 | 2005-10-12 | 拜奥根Idec马萨诸塞公司 | Nogo受体拮抗剂 |
| ES2215469B1 (es) | 2002-09-30 | 2005-12-16 | Bsh Electrodomesticos España, S.A. | Aparato de aire acondicionado. |
| ES2215470B1 (es) | 2002-09-30 | 2005-12-16 | Bsh Electrodomesticos España, S.A. | Aparato de aire acondicionado. |
| WO2004085648A2 (en) | 2003-03-19 | 2004-10-07 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
| BRPI0512500A (pt) | 2004-06-24 | 2008-03-11 | Biogen Idec Inc | tratamento ou condições envolvendo desmielinação |
| EP2329714A1 (en) | 2004-08-03 | 2011-06-08 | Biogen Idec MA Inc. | Influence of TAJ in the neuronal functions |
| WO2006124627A2 (en) * | 2005-05-12 | 2006-11-23 | Biogen Idec Ma Inc. | Methods of treating conditions involving neuronal degeneration |
| US7893032B2 (en) | 2005-07-07 | 2011-02-22 | Yale University | NgR variants and compositions thereof for suppressing axonal growth inhibition |
| RS53058B (sr) | 2005-07-08 | 2014-04-30 | Biogen Idec Ma Inc. | Sp35 antitela i njihova primena |
| CN101277974A (zh) | 2005-09-30 | 2008-10-01 | 阿伯特有限及两合公司 | 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途 |
| CN103215293B (zh) | 2006-01-27 | 2015-10-28 | 比奥根Ma公司 | Nogo受体拮抗剂 |
| EP2068866A4 (en) | 2006-07-24 | 2010-04-07 | Biogen Idec Inc | METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS |
| PL2081562T3 (pl) | 2006-09-20 | 2017-05-31 | The Board Of Regents Of The University Of Texas System | Sposoby dostarczania lotnych środków znieczulających do znieczulenia regionalnego i/lub zmniejszania bólu |
| US7906120B2 (en) * | 2006-11-21 | 2011-03-15 | Abbott Laboratories | Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) |
| PL2244737T3 (pl) | 2008-01-22 | 2020-05-18 | The Board Of Regents Of The University Of Texas System | Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| DK2982695T3 (da) | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
| SG181563A1 (en) | 2009-12-08 | 2012-07-30 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| ES2676725T3 (es) | 2012-01-27 | 2018-07-24 | AbbVie Deutschland GmbH & Co. KG | Composición y método para el diagnóstico y el tratamiento de enfermedades asociadas con la degeneración de las neuritas |
| EP2849787A4 (en) | 2012-05-14 | 2016-06-15 | Biogen Ma Inc | LINGO-2 ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING ENGINE NEURONS |
| MX2017009038A (es) | 2015-01-08 | 2017-10-25 | Biogen Ma Inc | Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes. |
| CN110488007A (zh) * | 2019-09-26 | 2019-11-22 | 天津华科泰生物技术有限公司 | 一种快速检测神经胶质纤维酸性蛋白的免疫层析检测卡及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4682999A (en) * | 1998-06-16 | 2000-01-05 | Human Genome Sciences, Inc. | 94 human secreted proteins |
| JP2005519584A (ja) * | 2001-10-22 | 2005-07-07 | ノバルティス アクチエンゲゼルシャフト | Ｎｏｇｏレセプターホモログおよびそれらの使用 |
-
2004
- 2004-01-30 BR BRPI0413426-5A patent/BRPI0413426A/pt not_active IP Right Cessation
- 2004-01-30 JP JP2006522535A patent/JP2007501612A/ja active Pending
- 2004-01-30 CN CNA2004800294122A patent/CN1926147A/zh active Pending
- 2004-01-30 WO PCT/US2004/002702 patent/WO2005016955A2/en not_active Ceased
- 2004-01-30 MX MXPA06001444A patent/MXPA06001444A/es unknown
- 2004-01-30 CA CA002535007A patent/CA2535007A1/en not_active Abandoned
- 2004-01-30 PL PL380274A patent/PL380274A1/pl not_active Application Discontinuation
- 2004-01-30 AU AU2004264405A patent/AU2004264405A1/en not_active Abandoned
- 2004-01-30 EP EP04707073A patent/EP1660517A4/en not_active Withdrawn
-
2006
- 2006-03-06 NO NO20061081A patent/NO20061081L/no not_active Application Discontinuation
- 2006-03-07 IS IS8339A patent/IS8339A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005016955A3 (en) | 2006-07-20 |
| JP2007501612A (ja) | 2007-02-01 |
| CN1926147A (zh) | 2007-03-07 |
| IS8339A (is) | 2006-03-07 |
| WO2005016955A2 (en) | 2005-02-24 |
| PL380274A1 (pl) | 2007-01-22 |
| MXPA06001444A (es) | 2006-05-15 |
| CA2535007A1 (en) | 2005-02-24 |
| EP1660517A4 (en) | 2006-10-04 |
| EP1660517A2 (en) | 2006-05-31 |
| NO20061081L (no) | 2006-04-18 |
| AU2004264405A1 (en) | 2005-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0413426A (pt) | antagonistas de receptor novo | |
| DK1534736T3 (da) | Nogo-receptorantagonister | |
| CY1111097T1 (el) | Πρωτεϊνη δεσμευσης του υποδοχεα nogo | |
| EP2526968A3 (en) | Nogo receptor antagonists | |
| WO2002068646A3 (en) | Mammalian cytokines; receptors; related reagents and methods | |
| EP1433792A3 (en) | Human receptor proteins, related reagents and methods | |
| EA200600376A1 (ru) | Антагонисты nogo-рецептора | |
| ATE470858T1 (de) | Opiatrezeptoren | |
| WO2003087331A3 (en) | Polyvalent cation-sensing receptor in atlantic salmon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S) |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |